Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma
Posted on 20 Nov 2026
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, which involves engineering a patient’s own immune cells to recognize and attack cancer cells, has transformed treatment for large B-cell lymphoma, an aggressive blood cancer. However, nearly half of patients either fail to respond or relapse within a year, highlighting the need for reliable predictors of treatment outcomes. New findings suggest that a blood-based RNA test may help identify patients more likely to benefit from CAR T-cell therapy before treatment begins.
Researchers at Cornell University and Dana-Farber Cancer Institute identified a cell-free RNA (cfRNA) gene expression signature associated with response to chimeric antigen receptor (CAR) T-cell therapy in patients with large B-cell lymphoma. The signature is derived from RNA fragments released into blood plasma by cells, potentially providing a noninvasive view of the tumor microenvironment. By capturing molecular signals from immune cells, structural cells, and blood vessel cells surrounding tumors, the approach may offer insights into treatment response without requiring tissue biopsies.
The study analyzed pretreatment plasma samples from 91 lymphoma patients receiving a specific CAR T-cell therapy product at Dana-Farber Cancer Institute. Participants, whose median age was 65, were evaluated across three separate groups. Researchers found that patients with higher scores for a lymph node-like gene expression signature were more likely to respond to treatment. Those with high signature scores also had an 80% lower risk of disease progression compared with patients with low scores.
The blood-based signature closely reflected findings from an earlier study that identified similar molecular patterns in tumor biopsy samples. Patients with above-median signature scores experienced significantly longer survival across all three groups, further supporting its potential prognostic value. Notably, the signature was absent from matched circulating immune cells, suggesting that plasma cfRNA captures biological activity within tumor-associated tissues rather than simply reflecting changes in the composition of circulating blood cells.
The study was published on November 18 in Cell Reports Medicine. Cornell University and Dana-Farber Cancer Institute collaborated on the work. The authors stated that the model requires validation in larger, multi-institution cohorts and that the findings have not been shown to change patient outcomes.
“CAR T-cell therapy is one of the major breakthroughs of the past couple of decades, but not every patient responds,” said Iwijn De Vlaminck, professor in the Meinig School of Biomedical Engineering in the Cornell Duffield College of Engineering.
“The study was focused on a specific patient group. The next step would be to expand that to other patients who are receiving CAR T therapy. Next would be validating across a cohort and seeing if this is reproducible across different contexts,” said Glory Feyisayo Agun, a doctoral student in De Vlaminck’s lab.
Related Links
Cornell University
Dana-Farber Cancer Institute